Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive

CompletedOBSERVATIONAL
Enrollment

669

Participants

Timeline

Start Date

March 29, 2016

Primary Completion Date

July 22, 2020

Study Completion Date

July 22, 2020

Conditions
Severe Vasomotor Symptom Associated With Menopause
Trial Locations (20)

10326

Dongguk University Ilsan Medical Center Obstetrics, Goyang-si

10447

Obstetrics / Grace Women's Hospital, Goyong-si

14647

Bucheon St. Mary Hospital The Catholic University of Korea, Bucheon-si

18442

Kimhyeonmi OBGY, Hwaseong-si

41940

Kyungpook National University Hospital, Obstetrics, Daegu

700-721

Kyungpook National University/Department of Internal Medicine (Cardiology), Jung-gu

01432

Dr. Wang's OB & GY Clinic, Seoul

425-707

Korea University Ansan Hospital, Ansan

463-811

Baylor Ewha Obgyn Clinic, Seongnam-si

602 739

Pusan University Hospital Obstetrics, Pusan

06591

Catholic Universith of Korea, Seoul ST. Mary's Hospital, Seoul

135-710

Samsung Medical Center, Sungkyunkwan Univ. School of Medicine, Kangnam-ku

05030

Konkuk University Medical Center, Seoul

110-744

Seoul National University Hospital / Department of Internal Medicine, Seoul

120-752

Severance Hospital, Yonsei University Health System, Seoul

138 736

Asan Medical Center, Seoul

139-707

Sanggye Paik Hospital-Inje University, Seoul

143-729

Konkuk University Medical Center, Seoul

156-755

Chungang University Hospital, Seoul

443-380

AJOU University Hospital, Suwon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02792504 - Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive | Biotech Hunter | Biotech Hunter